{"id":"telmisartan-amlodipine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":{"setId":"a30ff81d-420b-40ea-83d8-670260a93fff","title":"WIDAPLIK (TELMISARTAN, AMLODIPINE AND INDAPAMIDE) TABLET [AZURITY PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination of two antihypertensive agents with complementary mechanisms. Telmisartan is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and aldosterone release, reducing blood pressure and afterload. Amlodipine is a dihydropyridine calcium channel blocker that causes vasodilation by inhibiting calcium influx into vascular smooth muscle cells. Together, they provide synergistic blood pressure reduction.","oneSentence":"Telmisartan blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:58.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (essential hypertension)"}]},"trialDetails":[{"nctId":"NCT06041529","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2023-10-18","conditions":"Essential Hypertension","enrollment":198},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT02699645","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-09-28","conditions":"Intracerebral Haemorrhage (ICH), Hypertension","enrollment":1671},{"nctId":"NCT02373163","phase":"PHASE4","title":"INTERVENCION Trial","status":"COMPLETED","sponsor":"Prevencion","startDate":"2014-09-01","conditions":"Blood Pressure, High","enrollment":166},{"nctId":"NCT04518293","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-07-09","conditions":"Hypertension","enrollment":1385},{"nctId":"NCT04518306","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-06-14","conditions":"Hypertension","enrollment":755},{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT06282549","phase":"","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2022-06-08","conditions":"Essential Hypertension","enrollment":1219},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT03662620","phase":"PHASE1","title":"Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-10-05","conditions":"Hypertension","enrollment":67},{"nctId":"NCT06214832","phase":"","title":"An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine)","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2021-11-11","conditions":"Hypertension","enrollment":4000},{"nctId":"NCT00242814","phase":"PHASE4","title":"Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11-03","conditions":"Hypertension, Metabolic Syndrome X","enrollment":100},{"nctId":"NCT05144360","phase":"PHASE3","title":"Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension","status":"WITHDRAWN","sponsor":"EMS","startDate":"2022-08","conditions":"Hypertension Associated, Type II Diabetes Mellitus","enrollment":""},{"nctId":"NCT05155436","phase":"PHASE4","title":"Occurrence of Dyskalemia With Treatment for Hypertension","status":"COMPLETED","sponsor":"National Heart Foundation of Bangladesh","startDate":"2022-01-15","conditions":"Hypertension, Potassium Imbalance","enrollment":1090},{"nctId":"NCT05843162","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-06-01","conditions":"Essential Hypertension, Metabolic Syndrome","enrollment":116},{"nctId":"NCT03205137","phase":"","title":"Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-06-01","conditions":"Hypertension","enrollment":""},{"nctId":"NCT04218552","phase":"PHASE2","title":"Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-02-25","conditions":"Hypertension,Essential","enrollment":176},{"nctId":"NCT03474562","phase":"PHASE4","title":"High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2018-04-03","conditions":"ASCVD, Impaired Fasting Glucose, Hypertension","enrollment":100},{"nctId":"NCT03783754","phase":"NA","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2018-08-09","conditions":"Stroke, Cerebral Small Vessel Diseases, Intracerebral Hemorrhage","enrollment":4},{"nctId":"NCT04158076","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-01-23","conditions":"Hypercholesterolemia, Hypertension","enrollment":131},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03785067","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2020-02-27","conditions":"Cognitive Decline, Intracerebral Hemorrhage, Dementia, Vascular","enrollment":1},{"nctId":"NCT03319823","phase":"PHASE4","title":"Treating Nocturnal Hypertension and Nocturia in African American Men","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-10-25","conditions":"High Blood Pressure","enrollment":""},{"nctId":"NCT00421863","phase":"PHASE4","title":"Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study","status":"COMPLETED","sponsor":"Heart Care Foundation","startDate":"2005-02","conditions":"Hypertension","enrollment":1111},{"nctId":"NCT04667624","phase":"PHASE1","title":"Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-02-29","conditions":"Hypertension","enrollment":32},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT03021265","phase":"","title":"To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-01-20","conditions":"Hypertension","enrollment":676},{"nctId":"NCT02231788","phase":"PHASE4","title":"The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-06","conditions":"Hypertension","enrollment":217},{"nctId":"NCT03707899","phase":"PHASE1","title":"The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2018-12-13","conditions":"Hypertension With Dyslipidemia","enrollment":49},{"nctId":"NCT03956823","phase":"NA","title":"Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2019-08-01","conditions":"Hypertension","enrollment":300},{"nctId":"NCT03889145","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-12-19","conditions":"Healthy","enrollment":30},{"nctId":"NCT03860220","phase":"PHASE4","title":"The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin","status":"UNKNOWN","sponsor":"Hyo-Soo Kim","startDate":"2019-03-01","conditions":"Hypertension, Dyslipidemias","enrollment":304},{"nctId":"NCT03116516","phase":"PHASE1","title":"Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-04-21","conditions":"Hypertension, Hyperlipidemia","enrollment":62},{"nctId":"NCT03067688","phase":"PHASE3","title":"Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2017-04-11","conditions":"Hypertension, Hyperlipidemia","enrollment":202},{"nctId":"NCT01243268","phase":"","title":"A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-12-21","conditions":"Hypertension","enrollment":674},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT03088254","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2016-09-20","conditions":"Dyslipidemia With Hypertension","enrollment":126},{"nctId":"NCT03566316","phase":"PHASE3","title":"Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-11-24","conditions":"Hypertension With Hyperlipidemia","enrollment":134},{"nctId":"NCT01996085","phase":"NA","title":"Non-invasive Haemodynamic Assessment in Hypertension","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2013-01","conditions":"Arterial Hypertension","enrollment":144},{"nctId":"NCT03461081","phase":"PHASE1","title":"Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2017-05-07","conditions":"Hypertension With Hyperlipidemia","enrollment":32},{"nctId":"NCT03210532","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2016-10-07","conditions":"Hypertension, Dyslipidemia","enrollment":129},{"nctId":"NCT03247140","phase":"PHASE1","title":"The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2017-06-10","conditions":"Hypertension With Dyslipidemia","enrollment":40},{"nctId":"NCT02526875","phase":"PHASE4","title":"Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-04","conditions":"Hypertension","enrollment":208},{"nctId":"NCT03226340","phase":"PHASE4","title":"S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-12-02","conditions":"Essential Hypertension","enrollment":170},{"nctId":"NCT02121535","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-04","conditions":"Healthy","enrollment":72},{"nctId":"NCT02129192","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT02734355","phase":"PHASE4","title":"Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation","status":"COMPLETED","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2015-11","conditions":"Atrial Fibrillation","enrollment":64},{"nctId":"NCT02608242","phase":"PHASE1","title":"PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin","status":"TERMINATED","sponsor":"Yuhan Corporation","startDate":"2015-11","conditions":"Hypertension, Hyperlipidemia","enrollment":123},{"nctId":"NCT02951962","phase":"PHASE1","title":"A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2016-08","conditions":"Hypertension, Hyperlipidemia","enrollment":60},{"nctId":"NCT03032315","phase":"PHASE1","title":"Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-10-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT02739672","phase":"PHASE1","title":"Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-01-02","conditions":"Healthy","enrollment":40},{"nctId":"NCT02183675","phase":"PHASE1","title":"Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT01975246","phase":"PHASE3","title":"Add-on to Micamlo BP Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Hypertension","enrollment":309},{"nctId":"NCT02738632","phase":"PHASE3","title":"Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-05","conditions":"Essential Hypertension","enrollment":300},{"nctId":"NCT00509470","phase":"PHASE4","title":"Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":75},{"nctId":"NCT02933658","phase":"PHASE1","title":"Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2015-11","conditions":"Hypertension and Dyslipidemia","enrollment":71},{"nctId":"NCT02387619","phase":"PHASE1","title":"The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine","status":"COMPLETED","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2015-02","conditions":"Hypertension, Hyperlipidemia","enrollment":41},{"nctId":"NCT01911780","phase":"PHASE3","title":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07","conditions":"Hypertension","enrollment":132},{"nctId":"NCT02496910","phase":"PHASE1","title":"PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-06","conditions":"Hypertension","enrollment":180},{"nctId":"NCT01316419","phase":"","title":"Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-03","conditions":"Hypertension","enrollment":2089},{"nctId":"NCT02358824","phase":"PHASE1","title":"CKD-828 (80/5mg) Pharmacokinetic Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-02","conditions":"Hypertension","enrollment":48},{"nctId":"NCT01819220","phase":"PHASE4","title":"Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-04","conditions":"Hypertension","enrollment":16},{"nctId":"NCT02250833","phase":"PHASE1","title":"CKD-828 (80/5mg) Pharmacokinetic Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-09","conditions":"Hypertension","enrollment":69},{"nctId":"NCT02233218","phase":"PHASE1","title":"The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2014-07","conditions":"Healthy Male Volunteer","enrollment":60},{"nctId":"NCT02152969","phase":"PHASE1","title":"Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2014-05","conditions":"Hypertension","enrollment":66},{"nctId":"NCT02261064","phase":"PHASE1","title":"Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-12","conditions":"Healthy","enrollment":32},{"nctId":"NCT02259790","phase":"PHASE1","title":"Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-07","conditions":"Healthy","enrollment":30},{"nctId":"NCT02259803","phase":"PHASE1","title":"Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT02259829","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"Healthy","enrollment":84},{"nctId":"NCT02259816","phase":"PHASE1","title":"Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-05","conditions":"Healthy","enrollment":38},{"nctId":"NCT02259777","phase":"PHASE1","title":"Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT01353274","phase":"","title":"Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-05","conditions":"Hypertension","enrollment":1157},{"nctId":"NCT02213224","phase":"PHASE4","title":"Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2014-08","conditions":"Nonalcoholic Fatty Liver Disease (NAFLD)","enrollment":180},{"nctId":"NCT01181011","phase":"PHASE1","title":"Telmisartan, Amlodipine and Combination in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Healthy","enrollment":28},{"nctId":"NCT02193308","phase":"PHASE1","title":"Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"Healthy","enrollment":84},{"nctId":"NCT02194309","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00558064","phase":"PHASE3","title":"Filtered Trial for Amlodipine Non-responder","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Hypertension","enrollment":531},{"nctId":"NCT02177409","phase":"PHASE3","title":"Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Hypertension","enrollment":431},{"nctId":"NCT01222520","phase":"PHASE3","title":"Telmisartan 80mg Non-responder Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10","conditions":"Hypertension","enrollment":174},{"nctId":"NCT01286558","phase":"PHASE3","title":"Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-01","conditions":"Hypertension","enrollment":225},{"nctId":"NCT01103960","phase":"PHASE3","title":"An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-07","conditions":"Hypertension","enrollment":324},{"nctId":"NCT00618774","phase":"PHASE3","title":"An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-01","conditions":"Hypertension","enrollment":259},{"nctId":"NCT01204398","phase":"PHASE3","title":"Telmisartan+Amlodipine Fixed Dose Combination in Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-11","conditions":"Hypertension","enrollment":27},{"nctId":"NCT00558428","phase":"PHASE3","title":"Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Hypertension","enrollment":1098},{"nctId":"NCT00860262","phase":"PHASE3","title":"Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-03","conditions":"Hypertension","enrollment":858},{"nctId":"NCT00624052","phase":"PHASE3","title":"26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-03","conditions":"Hypertension","enrollment":838},{"nctId":"NCT02047175","phase":"PHASE1","title":"CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-02","conditions":"Hypertension, Hyperlipidemia","enrollment":64},{"nctId":"NCT01344629","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Healthy","enrollment":64},{"nctId":"NCT01278797","phase":"PHASE1","title":"Telmisartan and Amlodipine Versus Monocomponent Tablets","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-01","conditions":"Hypertension","enrollment":28},{"nctId":"NCT00281580","phase":"PHASE3","title":"Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Hypertension","enrollment":1461},{"nctId":"NCT00877929","phase":"PHASE3","title":"Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Hypertension","enrollment":706},{"nctId":"NCT00614380","phase":"PHASE3","title":"Open Label Study Telmisartan and Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-01","conditions":"Hypertension","enrollment":976},{"nctId":"NCT00553267","phase":"PHASE3","title":"Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-11","conditions":"Hypertension","enrollment":947},{"nctId":"NCT00550953","phase":"PHASE3","title":"Filtered Trial for Telmisartan 40mg Non-responder","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-10","conditions":"Hypertension","enrollment":314},{"nctId":"NCT01134393","phase":"PHASE3","title":"TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Hypertension","enrollment":502},{"nctId":"NCT00847262","phase":"PHASE4","title":"Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2008-06","conditions":"Hypertension, Obesity, Diabetes","enrollment":120},{"nctId":"NCT01983735","phase":"PHASE3","title":"Efficacy and Safety of TELMINUVO to Stage 2 Hypertension","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT00240474","phase":"PHASE4","title":"A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-12","conditions":"Hypertension","enrollment":1000},{"nctId":"NCT01842230","phase":"PHASE1","title":"Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-04","conditions":"Essential Hypertension, Hyperlipidemia","enrollment":24},{"nctId":"NCT01842256","phase":"PHASE1","title":"Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-04","conditions":"Essential Hypertension, Hyperlipidemia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":71,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Telmisartan + Amlodipine","genericName":"Telmisartan + Amlodipine","companyName":"Daewon Pharmaceutical Co., Ltd.","companyId":"daewon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telmisartan + Amlodipine, also known as Twynsta, is a combination medication used to treat hypertension. It works by blocking the type-1 angiotensin II receptor, a molecular target involved in blood pressure regulation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}